Kisunla is used to treat Alzheimer’s disease. It is an FDA-approved treatment for early symptomatic Alzheimer’s disease, including mild cognitive impairment and the mild dementia stage of the condition.
Approval Date
02-Jul-24
Data Exclusivity Expiry
02-Jul-28
Market Exclusivity Expiry
02-Jul-36
Commercial snapshot
Market performance & projections
Revenue ($M)
249
CAGR (%)
63.58%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
596
2027
953
2028
1,378
2029
1,783
2030
2,100
2031
2,422
2032
2,733
Molecule profile
Details & specifications
Molecule
Donanemab-Azbt
Innovator
ELI LILLY
Dosage Form
Intravenous Infusion
Strength
350 mg/20 mL
Therapeutic Category
Antialzheimer
Usage
To treat Alzheimer’s disease
Good to know
Frequently asked questions
Ready to act on this opportunity?
Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.